RxSight, Inc. (RXST) Stock

About RxSight, Inc.

RxSight, Inc. is led by CEO Ronald Kurtz, employs 498 people, headquartered in US, publicly traded since 2021.

RxSight, Inc. (RXST) stock trades at $5.02 with a market capitalization of $208.80M. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.14, reflecting a net loss over the last twelve months, price-to-book of 0.74, price-to-sales of 1.52. Over the past 52 weeks the stock has ranged between $4.43 and $13.22, and currently trades 62.0% below its 52-week high.

On profitability, RxSight, Inc. generates a return on equity (ROE) of -17.35% (negative, reflecting a net loss), return on capital employed of -20.24%, an operating margin of -35.82%, a net profit margin of -36.80%.

RxSight, Inc. by the numbers, 2019–2025

Between 2019 and 2025 RxSight, Inc. reported revenue of $2.0M rising to $134.0M, a change of +6600.0% across 7 years. Compounded, revenue has grown 55.0% a year over five years, 39.8% over three, -4.3% over the last twelve months. Net profit fell to $-39.0M.

Operating margin went from -2055.8% in 2019 to -35.8% in 2025, a gain of 2019.9 percentage points. The most recent net margin is -36.80%. On a trailing twelve-month basis to Jun '26, revenue is $128.0M and net profit $-47.0M.

Borrowings rose from $6.0M to $11.0M, cash from operations was $-16.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -32.9% over five years, and was -14.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

RxSight, Inc. (RXST) — frequently asked questions